Cribado de cáncer de pulmón con tomografía de baja dosis

El cáncer de pulmón continúa entre las principales causas de muerte por cáncer. Buena parte de los diagnósticos se producen cuando la enfermedad ya está avanzada, porque sus síntomas iniciales pueden confundirse con infecciones respiratorias, asma o bronquitis crónica. La detección precoz en personas asintomáticas con factores de riesgo podría reducir esta mortalidad, siempre que el beneficio se obtenga mediante un programa organizado y seguro.

La tomografía computarizada de baja dosis permite identificar nódulos pulmonares con mayor sensibilidad que la radiografía de tórax. Utilizada aisladamente, sin criterios de selección ni seguimiento protocolizado, no garantiza una reducción de la mortalidad y puede exponer a pacientes de bajo riesgo a procedimientos innecesarios. La evidencia más sólida corresponde a personas con una historia importante de tabaquismo.

En atención primaria se concentra el contacto con la mayoría de los fumadores, por lo que este nivel asistencial puede identificar candidatos, explicar el cribado y orientar hacia una 单位(rc? Spanish) de diagnóstico. No obstante, la consulta no debe sustituir un programa de cribado poblacional con controles de calidad,解读 (avoid Chinese) radiológica y rutas rápidas ante hallazgos suspicious.

La decisión institucional no consiste simplemente en adquirir un equipo de tomografía. Plantea dilemmas sobre benefits, absolute effect, resource use, equitable access and risk of missed follow-up. La evidencia actual favors implementing structured screening for selected high-risk people, while rejecting its extension to the general population without supporting data.

Evidencia de los ensayos clínicos

El ensayo North Lung Screening Trial (NLST) randomly assigned a high-risk population aged 55 to 74 years, with at least 30 pack-years of smoking, to annual low-dose CT or chest radiography. In the 11-year follow-up, lung cancer mortality was 20% lower in the CT group, while all-cause mortality decreased by a more modest 6.7%. These results support a real effect on outcomes attributable to cancer, not merely a greater diagnostic activity.

The NELSON trial, developed in the Netherlands and Belgium, also demonstrated a reduction in lung cancer mortality among men after repeated CT screening. At ten years, the relative reduction was approximately 24%, with less precise results in women because fewer participants were recruited and the baseline incidence was lower. Differences in incidence, follow-up and imaging protocols limit direct comparisons between both studies.

The evidence comes from enriched, selected populations whose risk profile does not resemble that of an average adult. Participants generally had substantial tobacco exposure and good adherence to repeated scans. Applying trial results to light smokers, never-smokers or people with a short smoking history would extrapolate beyond the available evidence and could produce a weaker balance between benefit and harm.

Beneficio absoluto y certeza de la evidencia

Relative reductions can make screening appear more effective than it is for an individual. In the trial populations, approximately 250 to 320 people had to undergo screening during a period of seven to ten years to prevent one death from lung cancer. This absolute effect varies according to age, smoking intensity, previous diagnoses and baseline risk, so informed decisions should use local data whenever possible.

Using the GRADE approach, the certainty of evidence is moderate for the reduction in lung cancer mortality and the net benefit of screening in the high-risk population. This supports a strong recommendation to offer low-dose CT when appropriate conditions are met. Certainty is lower for some harms, especially overdiagnosis and the consequences of false-positive findings, because these events are less frequent and heterogeneous.

A shared decision should translate relative effects into understandable absolute values. It must also address the possibility that a scan does not prevent cancer, that abnormalities usually prove benign and that a normal result does not exclude disease developing between examinations. The small reduction in all-cause mortality should be presented alongside the clearer effect on lung cancer mortality, without minimizing either outcome.

Riesgos del cribado y posibles daños

Most abnormalities detected by low-dose CT are benign. In the NLST, about 96% of positive results were classified as indeterminate; approximately 7–8% of participants underwent an invasive diagnostic procedure, and around 1% of those procedures caused complications. Newer nodule classification systems and standardized comparison with previous images can reduce unnecessary follow-up, but do not eliminate the problem.

Overdiagnosis means detecting a lung cancer that would never have caused symptoms or death during the person's lifetime. Its estimated frequency in the original NLST analysis was small, approximately 3%, although the statistical interval was wide and the estimate depended on follow-up and assumptions. Screening may also discover unrelated pulmonary or extrapulmonary findings, sometimes leading to additional imaging, laboratory tests or invasive interventions without improving outcomes.

The radiation dose of a screening examination is lower than that of a conventional diagnostic CT, but it accumulates over successive rounds. Most screening CT studies do not require intravenous contrast or sedation. For low-risk people, the combination of radiation exposure, anxiety, incidental findings and procedures of uncertain benefit is difficult to justify, particularly when no organized follow-up system is available.

Criterios de selección de los candidatos

The United States Preventive Services Task Force recommends annual low-dose CT for adults aged 50 to 80 years who have accumulated at least 20 pack-years, currently smoke or stopped during the previous 15 years. Other European and professional recommendations have traditionally used a higher age threshold and a exposure of 30 pack-years, although several countries are reviewing their criteria in light of more recent data.

These thresholds should not be interpreted as inviolable or identical in every setting. Risk prediction models may help resolve borderline cases, but their calibration varies across populations. Eligibility must also consider the time since smoking cessation, previous lung imaging, associated pulmonary disease and the possibility of benefiting from curative treatment.

Screening is intended for asymptomatic adults. People with suspicious symptoms, such as hemoptysis, persistent thoracic pain, unexplained weight loss or recurrent pneumonia, need an appropriate diagnostic evaluation, which may include contrast-enhanced CT, rather than a screening examination. Previous lung cancer, limited life expectancy and severe comorbidity are reasons to reassess the indication carefully.

Organización de un programa de cribado

An effective program requires more than access to CT. It needs a registry, systematic invitation, documentation of informed consent, standardized low-dose acquisition, structured reporting, an established protocol for pulmonary nodules and rapid access to diagnostic imaging, pulmonology, thoracic surgery and oncology. Each positive result must have a responsible clinician and a clearly assigned follow-up interval.

The imaging interval depends on the protocol and the characteristics of the nodule. Many programs use annual screening initially and consider extending it to two years after several stable examinations. Nodule management should follow validated systems such as Lung-RADS or an equivalent local protocol, including comparison with previous images, growth criteria, PET-CT, biopsy and multidisciplinary review when indicated.

Cost-effectiveness models generally favor organized screening in populations with high lung cancer risk, but results depend on participation, cancer incidence and the cost of subsequent diagnostic care. In Spain, implementation remains uneven across autonomous communities and is developing through screening initiatives and pilot programs. A quality registry and published performance indicators are essential to determine whether local programs reduce mortality or merely increase the number of detected nodules.

Papel de los profesionales de atención primaria

Primary care teams can update the smoking history, calculate pack-years and record the date of cessation. This information allows identification of people who may qualify under local criteria. Professionals must also explore symptoms that could make screening inappropriate and verify whether the patient has previously participated in a lung cancer screening program.

The consultation is an appropriate setting for decision support based on shared decisions. It should explain the expected benefit, the possibility of false-positive findings, the radiation exposure and the need for continued attendance. When a person is eligible, referral should lead to an accredited program rather than an isolated CT ordered without a management plan.

Tobacco cessation remains one of the most effective interventions for reducing lung cancer risk and should accompany every screening offer, even among people who accept CT. It is also necessary to establish a safety net: persistent or new respiratory symptoms must be evaluated diagnostically despite a recent normal screening result. Tracking attendance, communicating results and coordinating follow-up are therefore integral parts of primary care, not administrative tasks added afterward.

Subscribe to Rincón Docente de Medicina de Familia para receive critical analyses on clinical guidelines, systematic reviews and practical decisions in primary care, and share this evaluation with teams involved in the prevention and management of lung cancer.